The success of glioblastoma clinical trials will encouraged interest in blocking other potential effectors of immunosuppression including the soluble (such as IDO and TGF- β) and cellular (such as Treg cells and MDSCs) mediators of the process. This evidence concerns the gene IDO1 and glioblastoma.